Overview

• mRNA medicines firm's Q4 revenue fell due to reduced CSL collaboration activity

• Operating expenses for Q4 decreased, driven by lower manufacturing and clinical costs

• Net loss for Q4 was $29.1 mln, slightly improved from last year

Outlook

• Company extends cash runway into Q2 2028

• Arcturus expects slight decrease in general and administrative expenses

Result Drivers

• REDUCED COLLABORATION REVENUE - Revenue decline attributed to decreased activity in CSL collaboration, affecting supply agreements and milestone achievements

• LOWER OPERATING EXPENSES - Operating expenses decreased due to reduced manufacturing and clinical costs, particularly for LUNAR programs

Company press release: ID:nBw2MsXpga

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $21.50, about 157.5% above its March 2 closing price of $8.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)